Evidence map›Paper›PMID 38481985›Full record

ArticleRoyal Society open science2024

Metabolic reprogramming and signalling cross-talks in tumour-immune interaction: a system-level exploration.

Mudita Shukla, Rupa Bhowmick, Piyali Ganguli, Ram Rup Sarkar

Open access · goldAbstract read
In one paragraph

Article in Royal Society open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mudita ShuklaChemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India.
Rupa BhowmickChemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India.
Piyali GanguliChemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India.
Ram Rup SarkarChemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India.ORCID https://orcid.org/0000-0001-7115-163X
National Chemical Laboratory · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour-immune microenvironment (TIME) is pivotal in tumour progression and immunoediting. Within TIME, immune cells undergo metabolic adjustments impacting nutrient supply and the anti-tumour immune response. Metabolic reprogramming emerges as a promising approach to revert the immune response towards a pro-inflammatory state and conquer tumour dominance. This study proposes immunomodulatory mechanisms based on metabolic reprogramming and employs the regulatory flux balance analysis modelling approach, which integrates signalling, metabolism and regulatory processes. For the first time, a comprehensive system-level model is constructed to capture signalling and metabolic cross-talks during tumour-immune interaction and regulatory constraints are incorporated by considering the time lag between them. The model analysis identifies novel features to enhance the immune response while suppressing tumour activity. Particularly, altering the exchange of succinate and oxaloacetate between glioma and macrophage enhances the pro-inflammatory response of immune cells. Inhibition of glutamate uptake in T-cells disrupts the antioxidant mechanism of glioma and reprograms metabolism. Metabolic reprogramming through adenosine monophosphate (AMP)-activated protein kinase (AMPK), coupled with glutamate uptake inhibition, was identified as the most impactful combination to restore T-cell function. A comprehensive understanding of metabolism and gene regulation represents a favourable approach to promote immune cell recovery from tumour dominance.

Indexed as

metabolic reprogrammingsignalling-metabolic cross-talkssystem modellingtumour–immune interaction

Identifiers

PMID38481985
PMCPMC10933535
OpenAlexW4392750162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.